Elevated high-sensitivity C-reactive protein and the risk for cardiovascular events in chronic cardiac disease

Abstract Background High sensitivity C-reactive protein (hs-CRP) is a biomarker used for risk prediction cardiovascular disease by assessing low concentration of inflammation. This study aims to assess the event-free time composite outcome between patients different hs-CRP groups and possible predictive value event occurrence in with chronic cardiac disease. Methods Data from 607 consecutive referred assessment November 2017 October 2018 were reviewed retrospectively. Routine peripheral venous blood samples taken on day inclusion sent local laboratory, where laboratory parameters analyzed processed accordance standards. 570 who had measurement immunoturbidimetric assay included analysis classified into three (low-, medium- high-risk) (hs-CRP cut-off: <1, 1–3, >3 mg/L). Association (acute myocardial infarction, stroke, coronary intervention (percutaneous or bypass surgery) death) was determined Cox regression visualized Kaplan Meier curves. Results In total, our cardiology outpatient clinic this study. Cohorts formed according groups, 209 (36.7%), 226 (39.6%) 135 (23.7%) as low-, high-risk, respectively. The endpoint occurred 93 (19.1%) 486 available follow-up. Events 29 (16.3%), 30 (15.7%), 34 (29.1%) high-risk group, respectively (p=0.016). There significant difference survival low- medium-risk compared group (p=0.015). shown Kaplan-Meier plot (log rank test, p=0.01) (Figure 1). Univariate proportional-hazard identified age, hypertension, diabetes, hyperlipidemia, artery disease, cerebrovascular log(NT-proBNP) creatinine predictors primary outcome. multivariable age found be highly an during follow-up, while categorized appeared predict lower likelihood events (Table Conclusions Cardiovascular more likely occur older, mg/L history However, inflammation markers alone may play secondary role other established factors, elevated CRP appears helpful detect higher further mortality. Funding Acknowledgement Type funding sources: None.